Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884819 | 1.00 | HTR2C (0.47) | HTR2CHTR2AMMP2ADAMTS5HTR2B | |
| SCHEMBL24454076 | 0.84 | PIM1 (0.43) | HTR2CHTR2AHTR2BGSK3BROCK2 | |
| SCHEMBL24454244 | 0.84 | PIM1 (0.43) | HTR2CHTR2AHTR2BGSK3BROCK2 | |
| SCHEMBL21098921 | 0.81 | HTR2C (0.44) | HTR2CHTR2AHTR2BGSK3BROCK2 | |
| SCHEMBL21098920 | 0.81 | HTR2C (0.44) | HTR2CHTR2AHTR2BGSK3BROCK2 | |
| SCHEMBL17884953 | 0.80 | HTR2C (0.46) | HTR2CHTR2AHTR2BGSK3BROCK2 | |
| SCHEMBL30609691 | 0.80 | HTR2C (0.46) | HTR2CHTR2AHTR2BGSK3BROCK2 | |
| SCHEMBL23777597 | 0.78 | MGLL (0.38) | MMP2ADAMTS5ROCK1 | |
| SCHEMBL23777599 | 0.78 | MGLL (0.38) | MMP2ADAMTS5ROCK1 | |
| SCHEMBL21262364 | 0.78 | HTR2C (0.46) | HTR2CHTR2AHTR2BGSK3BLATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2C 2380/4885HTR2A 2074/4885MMP2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.